

Maria Gavriatopoulou

List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/5384146/publications.pdf](https://exaly.com/author-pdf/5384146/publications.pdf)

Version: 2024-02-01

245
papers

6,531
citations

76893

40
h-index

95858

68
g-index

246
all docs

246
docs citations

246
times ranked

7450
citing authors

#	ARTICLE	IF	CITATIONS
1	Oral Selinexorâ€“Dexamethasone for Triple-Class Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2019, 381, 727-738.	27.3	460
2	Organ-specific manifestations of COVID-19 infection. <i>Clinical and Experimental Medicine</i> , 2020, 20, 493-506.	3.7	351
3	Emerging treatment strategies for COVID-19 infection. <i>Clinical and Experimental Medicine</i> , 2021, 21, 167-179.	3.7	232
4	Pathogenesis of bone disease in multiple myeloma: from bench to bedside. <i>Blood Cancer Journal</i> , 2018, 8, 7.	6.4	219
5	Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. <i>Lancet, The</i> , 2020, 396, 1563-1573.	14.0	188
6	Primary therapy of WaldenstrÃ¶m macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). <i>Blood</i> , 2013, 122, 3276-3282.	1.4	180
7	Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose. <i>Blood</i> , 2021, 137, 3674-3676.	1.4	130
8	Epidemiology and organ specific sequelae of post-acute COVID19: A narrative review. <i>Journal of Infection</i> , 2021, 83, 1-16.	3.3	127
9	Oncology during the COVIDâ€™19 pandemic: challenges, dilemmas and the psychosocial impact on cancer patients (Review). <i>Oncology Letters</i> , 2020, 20, 441-447.	1.8	115
10	Dexamethasone, rituximab, and cyclophosphamide as primary treatment of WaldenstrÃ¶m macroglobulinemia: final analysis of a phase 2 study. <i>Blood</i> , 2015, 126, 1392-1394.	1.4	108
11	The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment. <i>Blood Cancer Journal</i> , 2021, 11, 138.	6.4	103
12	Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis. <i>Journal of Clinical Oncology</i> , 2020, 38, 3252-3260.	1.7	102
13	Reversibility of Renal Impairment in Patients With Multiple Myeloma Treated With Bortezomib-Based Regimens: Identification of Predictive Factors. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 302-306.	1.4	101
14	Cardiac and renal complications of carfilzomib in patients with multiple myeloma. <i>Blood Advances</i> , 2017, 1, 449-454.	5.4	89
15	A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis. <i>Blood</i> , 2012, 119, 5384-5390.	1.4	88
16	Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients with multiple myeloma: A single center experience on 228 patients. <i>American Journal of Hematology</i> , 2012, 87, 861-864.	4.3	81
17	European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. <i>Leukemia</i> , 2018, 32, 1883-1898.	7.4	81
18	Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study. <i>Lancet Oncology, The</i> , 2022, 23, 65-76.	10.9	80

#	ARTICLE	IF	CITATIONS
19	Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis. <i>American Journal of Hematology</i> , 2016, 91, 499-502.	4.3	73
20	Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma. <i>Haematologica</i> , 2017, 102, 593-599.	3.6	72
21	Treatment of light chain deposition disease with bortezomib and dexamethasone. <i>Haematologica</i> , 2009, 94, 300-302.	3.6	70
22	Progression Risk Stratification of Asymptomatic Waldenström Macroglobulinemia. <i>Journal of Clinical Oncology</i> , 2019, 37, 1403-1411.	1.7	65
23	Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents. <i>Leukemia Research</i> , 2010, 34, 1395-1397.	0.9	64
24	Dickkopf-1: a suitable target for the management of myeloma bone disease. <i>Expert Opinion on Therapeutic Targets</i> , 2009, 13, 839-848.	3.4	62
25	BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years. <i>Blood</i> , 2017, 129, 456-459.	1.4	62
26	Lenalidomide in patients with POEMS syndrome: a systematic review and pooled analysis. <i>Leukemia and Lymphoma</i> , 2014, 55, 2018-2023.	1.3	57
27	Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom's macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH). <i>Leukemia Research</i> , 2010, 34, 1340-1343.	0.9	56
28	Re-evaluation of prognostic markers including staging, serum free light chains or their ratio and serum lactate dehydrogenase in multiple myeloma patients receiving novel agents. <i>Hematological Oncology</i> , 2013, 31, 96-102.	1.8	55
29	Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies. <i>American Journal of Hematology</i> , 2015, 90, E60-5.	4.3	55
30	The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents. <i>Blood</i> , 2018, 131, 464-467.	1.4	54
31	Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. <i>Leukemia</i> , 2020, 34, 2430-2440.	7.4	54
32	A revised international prognostic score system for Waldenström's macroglobulinemia. <i>Leukemia</i> , 2019, 33, 2654-2661.	7.4	53
33	Biology and treatment of myeloma related bone disease. <i>Metabolism: Clinical and Experimental</i> , 2018, 80, 80-90.	3.5	49
34	Renal outcomes in patients with AL amyloidosis: Prognostic factors, renal response and the impact of therapy. <i>American Journal of Hematology</i> , 2017, 92, 632-639.	4.3	48
35	Multiple Myeloma and Thrombosis: Prophylaxis and Risk Prediction Tools. <i>Cancers</i> , 2020, 12, 191.	3.8	48
36	Efficacy of Panobinostat for the Treatment of Multiple Myeloma. <i>Journal of Oncology</i> , 2020, 2020, 1-11.	1.4	46

#	ARTICLE	IF	CITATIONS
37	Prophylactic antibiotics for the prevention of neutropenic fever in patients undergoing autologous stem cell transplantation: Results of a single institution, randomized phase 2 trial. <i>American Journal of Hematology</i> , 2010, 85, 863-867.	4.3	44
38	Competing risk survival analysis in patients with symptomatic Waldenstrom macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy. <i>Haematologica</i> , 2015, 100, e446-e449.	3.6	44
39	Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis. <i>Blood</i> , 2018, 131, 1568-1575.	1.4	44
40	Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study. <i>Cancers</i> , 2021, 13, 4480.	3.8	44
41	No significant improvement in the outcome of patients with Waldenström's macroglobulinemia treated over the last 25 years. <i>American Journal of Hematology</i> , 2011, 86, 479-483.	4.3	43
42	Lack of survival improvement with novel anti-myeloma agents for patients with multiple myeloma and central nervous system involvement: the Greek Myeloma Study Group experience. <i>Annals of Hematology</i> , 2015, 94, 2033-2042.	1.8	43
43	Multiple myeloma: Role of autologous transplantation. <i>Cancer Treatment Reviews</i> , 2020, 82, 101929.	7.8	42
44	Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens. <i>American Journal of Hematology</i> , 2013, 88, 765-770.	4.3	40
45	Detection of MYD88 and CXCR4 mutations in cell-free DNA of patients with IgM monoclonal gammopathies. <i>Leukemia</i> , 2018, 32, 2617-2625.	7.4	40
46	Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis. <i>Blood Cancer Journal</i> , 2018, 8, 46.	6.4	39
47	Poor neutralizing antibody responses in 106 patients with WM after vaccination against SARS-CoV-2: a prospective study. <i>Blood Advances</i> , 2021, 5, 4398-4405.	5.4	39
48	Kinetics of Anti-SARS-CoV-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers. <i>Cells</i> , 2021, 10, 1942.	4.2	38
49	Clinical and prognostic significance of serum levels of von Willebrand factor and ADAMTS-13 antigens in AL amyloidosis. <i>Blood</i> , 2016, 128, 405-409.	1.4	37
50	Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone. <i>Blood Advances</i> , 2019, 3, 3002-3009.	5.4	37
51	A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis. <i>Blood</i> , 2016, 128, 646-646.	1.4	37
52	Late-onset hematological complications post COVID-19: An emerging medical problem for the hematologist. <i>American Journal of Hematology</i> , 2022, 97, 119-128.	4.3	36
53	Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group. <i>Blood Cancer Journal</i> , 2018, 8, 31.	6.4	35
54	Minimal Residual Disease in Multiple Myeloma: Current Landscape and Future Applications With Immunotherapeutic Approaches. <i>Frontiers in Oncology</i> , 2020, 10, 860.	2.9	35

#	ARTICLE	IF	CITATIONS
55	The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: Final results on 205 patients of the Greek myeloma study group. <i>American Journal of Hematology</i> , 2014, 89, 34-40.	4.3	33
56	Early and late endocrine complications of COVID-19. <i>Endocrine Connections</i> , 2021, 10, R229-R239.	2.0	32
57	Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma. <i>Annals of Hematology</i> , 2020, 99, 1049-1061.	1.8	31
58	SARS-CoV-2 Vaccines in Patients With Multiple Myeloma. <i>HemaSphere</i> , 2021, 5, e547.	2.7	31
59	Olive oil intake and cancer risk: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2022, 17, e0261649.	2.5	31
60	Disappearing liver metastases: A systematic review of the current evidence. <i>Surgical Oncology</i> , 2019, 29, 7-13.	1.6	30
61	Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine. <i>Clinical and Experimental Medicine</i> , 2022, 22, 319-323.	3.7	30
62	Semaphorin 4D correlates with increased bone resorption, hypercalcemia, and disease stage in newly diagnosed patients with multiple myeloma. <i>Blood Cancer Journal</i> , 2018, 8, 42.	6.4	29
63	Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment. <i>European Journal of Haematology</i> , 2010, 85, 1-5.	2.2	28
64	Current treatments for renal failure due to multiple myeloma. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 2165-2177.	1.9	28
65	Booster BNT162b2 optimizes SARS-CoV-2 humoral response in patients with myeloma: the negative effect of anti-BCMA therapy. <i>Blood</i> , 2022, 139, 1409-1412.	1.4	28
66	COVID-19: time to flatten the infodemic curve. <i>Clinical and Experimental Medicine</i> , 2021, 21, 161-165.	3.7	27
67	High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents. <i>Leukemia Research</i> , 2010, 34, 399-402.	0.9	26
68	Peripheral Blood Immune Profiling of Convalescent Plasma Donors Reveals Alterations in Specific Immune Subpopulations Even at 2 Months Post SARS-CoV-2 Infection. <i>Viruses</i> , 2021, 13, 26.	3.4	26
69	Toll-Like Receptor 4 Activation Promotes Multiple Myeloma Cell Growth and Survival Via Suppression of The Endoplasmic Reticulum Stress Factor Chop. <i>Scientific Reports</i> , 2019, 9, 3245.	3.4	25
70	High Prevalence of Anti-PF4 Antibodies Following ChAdOx1 nCov-19 (AZD1222) Vaccination Even in the Absence of Thrombotic Events. <i>Vaccines</i> , 2021, 9, 712.	4.5	25
71	Robust Neutralizing Antibody Responses 6 Months Post Vaccination with BNT162b2: A Prospective Study in 308 Healthy Individuals. <i>Life</i> , 2021, 11, 1077.	2.5	25
72	Hematologic and renal improvement of monoclonal immunoglobulin deposition disease after treatment with bortezomib-based regimens. <i>Leukemia and Lymphoma</i> , 2017, 58, 1832-1839.	1.3	24

#	ARTICLE	IF	CITATIONS
73	Efficacy of lenalidomide as salvage therapy for patients with AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2018, 25, 234-241.	3.1	24
74	Deep Phenotyping Reveals Distinct Immune Signatures Correlating with Prognostication, Treatment Responses, and MRD Status in Multiple Myeloma. <i>Cancers</i> , 2020, 12, 3245.	3.8	24
75	Longer procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: results of the prospective ROADMAP-MM-CAT study. <i>Blood Cancer Journal</i> . 2018, 8, 102.	6.4	23
76	Early Relapse After Autologous Transplant Is Associated With Very Poor Survival and Identifies an Ultra-High-Risk Group of Patients With Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 445-452.	0.4	23
77	Reactive Vasodilation Predicts Mortality in Primary Systemic Light-Chain Amyloidosis. <i>Circulation Research</i> , 2019, 125, 744-758.	4.6	22
78	Next generation flow cytometry for MRD detection in patients with AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2021, 28, 19-23.	3.1	22
79	Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia: Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 40-51.	1.7	22
80	Current Approaches in the Management of Hepatic Adenomas. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 199-209.	1.8	21
81	Consolidation therapy with the combination of bortezomib and lenalidomide (VR) without dexamethasone in multiple myeloma patients after transplant: Effects on survival and bone outcomes in the absence of bisphosphonates. <i>American Journal of Hematology</i> , 2019, 94, 400-407.	4.3	21
82	Carfilzomib-associated renal toxicity is common and unpredictable: a comprehensive analysis of 114 multiple myeloma patients. <i>Blood Cancer Journal</i> , 2020, 10, 109.	6.4	21
83	Weekly selinexor, bortezomib, and dexamethasone (SVd) versus twice weekly bortezomib and dexamethasone (Vd) in patients with multiple myeloma (MM) after one to three prior therapies: Initial results of the phase III BOSTON study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 8501-8501.	1.7	21
84	Comparison of Neutralizing Antibody Responses at 6 Months Post Vaccination with BNT162b2 and AZD1222. <i>Biomedicines</i> , 2022, 10, 338.	3.2	21
85	Bortezomib as a Treatment Option in Patients With Waldenström Macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 110-117.	0.4	20
86	Impact of Minimal Residual Disease Detection by Next-Generation Flow Cytometry in Multiple Myeloma Patients with Sustained Complete Remission after Frontline Therapy. <i>HemaSphere</i> , 2019, 3, e300.	2.7	20
87	Anti-BCMA antibodies in the future management of multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 319-326.	2.4	19
88	COVID-19 Vaccines in Patients With Cancer—A Welcome Addition, but There Is Need for Optimization. <i>JAMA Oncology</i> , 2021, 7, 1113.	7.2	19
89	Timing and impact of a deep response in the outcome of patients with systemic light chain (AL) amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2021, 28, 3-11.	3.1	18
90	Myeloma patients with COVID-19 have superior antibody responses compared to patients fully vaccinated with the BNT162b2 vaccine. <i>British Journal of Haematology</i> , 2022, 196, 356-359.	2.6	18

#	ARTICLE	IF	CITATIONS
91	Comparison of MRI Features of Fat Fraction and ADC for Early Treatment Response Assessment in Participants with Multiple Myeloma. <i>Radiology</i> , 2022, 304, 137-144.	7.4	18
92	Genetic factors related with early onset of osteonecrosis of the jaw in patients with multiple myeloma under zoledronic acid therapy. <i>Leukemia and Lymphoma</i> , 2017, 58, 2304-2309.	1.3	17
93	Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone. <i>Blood Advances</i> , 2019, 3, 4095-4103.	5.4	17
94	Clinical characteristics and outcomes of oligosecretory and non-secretory multiple myeloma. <i>Annals of Hematology</i> , 2020, 99, 1251-1255.	1.8	17
95	Sustained but Declining Humoral Immunity Against SARS-CoV-2 at 9 Months Postvaccination With BNT162b2: A Prospective Evaluation in 309 Healthy Individuals. <i>HemaSphere</i> , 2022, 6, e677.	2.7	17
96	Lenalidomide-associated pneumonitis in patients with plasma cell dyscrasias. <i>American Journal of Hematology</i> , 2011, 86, 882-884.	4.3	16
97	Neutrophil Gelatinase-associated Lipocalin and Cystatin C Are Sensitive Markers of Renal Injury in Patients With Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 29-35.	0.4	16
98	Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma. <i>Blood Cancer Journal</i> , 2020, 10, 25.	6.4	16
99	Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. <i>American Journal of Hematology</i> , 2021, 96, 708-718.	4.3	16
100	Metabolic Disorders in Multiple Myeloma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11430.	4.2	16
101	Applications of monoclonal antibodies for the treatment of hematological malignancies. <i>Expert Opinion on Biological Therapy</i> , 2009, 9, 207-220.	3.1	15
102	Meat, fish, dairy products and risk of hematological malignancies in adults – a systematic review and meta-analysis of prospective studies. <i>Leukemia and Lymphoma</i> , 2019, 60, 1978-1990.	1.3	15
103	Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents. <i>Blood Cancer Journal</i> , 2020, 10, 40.	6.4	15
104	Daratumumab-based therapy for patients with monoclonal gammopathy of renal significance. <i>British Journal of Haematology</i> , 2021, 193, 113-118.	2.6	15
105	Carfilzomib-induced endothelial dysfunction, recovery of proteasome activity, and prediction of cardiovascular complications: a prospective study. <i>Leukemia</i> , 2021, 35, 1418-1427.	7.4	15
106	SARS-CoV-2 neutralizing antibodies after first vaccination dose in breast cancer patients receiving CDK4/6 inhibitors. <i>Breast</i> , 2021, 60, 58-61.	2.2	15
107	Upfront Daratumumab With Lenalidomide and Dexamethasone for POEMS Syndrome. <i>HemaSphere</i> , 2020, 4, e381.	2.7	14
108	Recovery of Innate Immune Cells and Persisting Alterations in Adaptive Immunity in the Peripheral Blood of Convalescent Plasma Donors at Eight Months Post SARS-CoV-2 Infection. <i>Microorganisms</i> , 2021, 9, 546.	3.6	14

#	ARTICLE	IF	CITATIONS
109	Emerging treatment approaches for myeloma-related bone disease. <i>Expert Review of Hematology</i> , 2017, 10, 217-228.	2.2	13
110	<p></p>Evaluating ibrutinib in the treatment of symptomatic Waldenström's macroglobulinemia<p></p>. <i>Journal of Blood Medicine</i> , 2019, Volume 10, 291-300.	1.7	13
111	The Role of Low Dose Whole Body CT in the Detection of Progression of Patients with Smoldering Multiple Myeloma. <i>Blood Cancer Journal</i> , 2020, 10, 93.	6.4	13
112	Cholangiocarcinoma: investigations into pathway-targeted therapies. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 765-773.	2.4	13
113	A Cancer-Related microRNA Signature Shows Biomarker Utility in Multiple Myeloma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13144.	4.2	13
114	Angiogenesis in Waldenström's Macroglobulinemia. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 46-49.	1.4	12
115	Rituximab-Based Treatments in Waldenström's Macroglobulinemia. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 59-61.	1.4	12
116	Current treatment options and investigational drugs for Waldenström's Macroglobulinemia. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 197-205.	4.1	12
117	Micronutrient Intake and Risk of Hematological Malignancies in Adults: A Systematic Review and Meta-analysis of Cohort Studies. <i>Nutrition and Cancer</i> , 2018, 70, 821-839.	2.1	12
118	Characterization of a PERK Kinase Inhibitor with Anti-Myeloma Activity. <i>Cancers</i> , 2020, 12, 2864.	3.8	12
119	<p></p>Clinical Utility of Selinexor/Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma: A Review of Current Evidence and Patient Selection<p></p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 6405-6416.	2.0	12
120	Cell-free DNA analysis for the detection of MYD88 and CXCR4 mutations in IgM monoclonal gammopathies; an update with clinicopathological correlations. <i>American Journal of Hematology</i> , 2020, 95, E148-E150.	4.3	12
121	A Molecular Signature of Circulating MicroRNA Can Predict Osteolytic Bone Disease in Multiple Myeloma. <i>Cancers</i> , 2021, 13, 3877.	3.8	12
122	High levels of serum angiogenic growth factors in patients with AL amyloidosis: comparisons with normal individuals and multiple myeloma patients. <i>British Journal of Haematology</i> , 2010, 150, 587-591.	2.6	11
123	Updates on thrombotic events associated with multiple myeloma. <i>Expert Review of Hematology</i> , 2019, 12, 355-365.	2.2	11
124	Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group. <i>American Journal of Hematology</i> , 2019, 94, E146-E149.	4.3	11
125	Involvement of small nerve fibres and autonomic nervous system in AL amyloidosis: comprehensive characteristics and clinical implications. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2020, 27, 103-110.	3.1	11
126	Current and novel BTK inhibitors in Waldenström's macroglobulinemia. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 204062072198958.	2.6	11

#	ARTICLE	IF	CITATIONS
127	Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. <i>Journal of Hematology and Oncology</i> , 2021, 14, 59.	17.2	11
128	Real-World Treatment of Patients With Relapsed/Refractory Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 379-385.	0.4	11
129	miRNA-seq and clinical evaluation in multiple myeloma: miR-181a overexpression predicts short-term disease progression and poor post-treatment outcome. <i>British Journal of Cancer</i> , 2022, 126, 79-90.	6.5	11
130	Expression of CCL3 by Neoplastic Cells in Patients with Waldenström's Macroglobulinemia: An Immunohistochemical Study in Bone Marrow Biopsies of 67 Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 115-117.	0.4	10
131	Management of multiple myeloma bone disease: impact of treatment on renal function. <i>Expert Review of Hematology</i> , 2018, 11, 881-888.	2.2	10
132	Effect of induction therapy with lenalidomide, doxorubicin and dexamethasone on bone remodeling and angiogenesis in newly diagnosed multiple myeloma. <i>International Journal of Cancer</i> , 2019, 145, 559-568.	5.2	10
133	Emerging Insights Into the Role of the Hippo Pathway in Multiple Myeloma and Associated Bone Disease. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 57-62.	0.4	10
134	Overweight/Obesity and Monoclonal Gammopathy of Undetermined Significance. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 361-367.	0.4	10
135	Occupational Exposure and Multiple Myeloma Risk: An Updated Review of Meta-Analyses. <i>Journal of Clinical Medicine</i> , 2021, 10, 4179.	2.4	10
136	The extended 4-year follow-up results of the ELOQUENT-2 trial. <i>Oncotarget</i> , 2019, 10, 82-83.	1.9	10
137	Pembrolizumab in endometrial cancer: Where we stand now (Review). <i>Oncology Letters</i> , 2021, 22, 821.	1.8	10
138	Immunological Response to COVID-19 Vaccination in Ovarian Cancer Patients Receiving PARP Inhibitors. <i>Vaccines</i> , 2021, 9, 1148.	4.5	10
139	Determination of MYD88L265P mutation fraction in IgM monoclonal gammopathies. <i>Blood Advances</i> , 2022, 6, 189-199.	5.4	10
140	Chromosome 1q21 aberrations identify ultra-high-risk myeloma with prognostic and clinical implications. <i>American Journal of Hematology</i> , 2022, 97, 1142-1149.	4.3	10
141	Phase 2 study of ofatumumab, fludarabine and cyclophosphamide in relapsed/refractory Waldenström's macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2017, 58, 1506-1508.	1.3	9
142	Clear cell chondrosarcoma of the lung: Diagnostic features of a rare pulmonary tumor. <i>Respiratory Medicine Case Reports</i> , 2018, 23, 52-54.	0.4	9
143	Pulmonary function abnormalities are common in patients with multiple myeloma and are independently associated with worse outcome. <i>Annals of Hematology</i> , 2019, 98, 1427-1434.	1.8	9
144	Vulnerability variables among octogenarian myeloma patients: a single-center analysis of 110 patients. <i>Leukemia and Lymphoma</i> , 2019, 60, 619-628.	1.3	9

#	ARTICLE	IF	CITATIONS
145	Long PFS of more than 7 years is achieved in 9% of myeloma patients in the era of conventional chemotherapy and of first-generation novel anti-myeloma agents: a single-center experience over 20-year period. <i>Annals of Hematology</i> , 2020, 99, 1257-1264.	1.8	9
146	Real-world data on incidence, clinical characteristics and outcome of patients with macrofocal multiple myeloma (MFMM) in the era of novel therapies: A study of the Greco-Israeli collaborative myeloma working group. <i>American Journal of Hematology</i> , 2020, 95, 465-471.	4.3	9
147	Monitoring Plasma Cell Dyscrasias With Cell-free DNA Analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e905-e909.	0.4	9
148	Carfilzomib Improves Bone Metabolism in Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results of the CarMMA Study. <i>Cancers</i> , 2021, 13, 1257.	3.8	9
149	How I treat elderly patients with plasma cell dyscrasias. <i>Aging</i> , 2018, 10, 4248-4268.	3.1	9
150	Short progression-free survival predicts for poor overall survival in older patients with multiple myeloma treated upfront with novel agent-based therapy. <i>European Journal of Haematology</i> , 2011, 87, 323-329.	2.2	8
151	Increased expression of cyclin-D1 on trephine bone marrow biopsies independently predicts for shorter overall survival in patients with multiple myeloma treated with novel agents. <i>American Journal of Hematology</i> , 2012, 87, 734-736.	4.3	8
152	TLR4 polymorphisms are associated with progression and survival of patients with symptomatic myeloma. <i>British Journal of Haematology</i> , 2016, 172, 44-47.	2.6	8
153	Elotuzumab in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 921-928.	2.4	8
154	Treatment of Bing-Neel syndrome with first line sequential chemoimmunotherapy. <i>Medicine (United States)</i> , 2019, 98, 111-115.	1.1	10
155	Whole-Body Low-Dose CT in Multiple Myeloma: Diagnostic Value of Appendicular Medullary Patterns of Attenuation. <i>American Journal of Roentgenology</i> , 2021, 216, 742-751.	2.2	8
156	The Emerging Role of Immunotherapy in Intrahepatic Cholangiocarcinoma. <i>Vaccines</i> , 2021, 9, 422.	4.5	8
157	Aberrant Plasma Cell Contamination of Peripheral Blood Stem Cell Autografts, Assessed by Next-Generation Flow Cytometry, Is a Negative Predictor for Deep Response Post Autologous Transplantation in Multiple Myeloma; A Prospective Study in 199 Patients. <i>Cancers</i> , 2021, 13, 4047.	3.8	8
158	Consolidation with a short course of daratumumab in patients with AL amyloidosis or light chain deposition disease. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2021, 28, 259-266.	3.1	8
159	Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study. <i>BMC Cancer</i> , 2021, 21, 993.	2.6	8
160	Elucidating Carfilzomib-Induced Cardiotoxicity in an In Vivo Model of Aging: Prophylactic Potential of Metformin. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10956.	4.2	8
161	Preliminary Clinical Response Data from a Phase 1b Study of Mavoxixafor in Combination with Ibrutinib in Patients with Waldenström's Macroglobulinemia with MYD88 and CXCR4 Mutations. <i>Blood</i> , 2021, 138, 1362-1362.	1.4	8
162	tRNA Derivatives in Multiple Myeloma: Investigation of the Potential Value of a tRNA-Derived Molecular Signature. <i>Biomedicines</i> , 2021, 9, 1811.	3.2	8

#	ARTICLE	IF	CITATIONS
163	Dynamic contrast-enhanced magnetic resonance imaging parameters correlate with advanced revised-ISS and angiopoietin-1/angiopoietin-2 ratio in patients with multiple myeloma. <i>Annals of Hematology</i> , 2017, 96, 1707-1714.	1.8	7
164	Multiple myeloma: Current and future management in the aging population. <i>Maturitas</i> , 2020, 138, 8-13.	2.5	7
165	Antibody therapies for multiple myeloma. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 295-303.	3.1	7
166	Exercise-Induced Changes in Tumor Growth via Tumor Immunity. <i>Sports</i> , 2021, 9, 46.	1.7	7
167	Antibody Response After Initial Vaccination for SARS-CoV-2 in Patients With Amyloidosis. <i>HemaSphere</i> , 2021, 5, e614.	2.7	7
168	Circulating Levels of the Wnt Inhibitors Dickkopf-1 and Sclerostin In Different Phases of Multiple Myeloma: Alterations Post-Therapy with Lenalidomide and Dexamethasone with or without Bortezomib. <i>Blood</i> , 2010, 116, 2963-2963.	1.4	7
169	Semaphorin-4D and Plexin-B1 Are Elevated in Multiple Myeloma Microenvironment and Possibly Contribute in the Development of Lytic Bone Disease. <i>Blood</i> , 2012, 120, 1819-1819.	1.4	7
170	Treatment with abiraterone or enzalutamide does not impair immunological response to COVID-19 vaccination in prostate cancer patients. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 117-118.	4.0	7
171	Daratumumab with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment: Results on Efficacy and Safety of the Phase 2 Dare Study. <i>Blood</i> , 2020, 136, 48-49.	1.4	7
172	Predictive Factors for Neutralizing Antibody Levels Nine Months after Full Vaccination with BNT162b2: Results of a Machine Learning Analysis. <i>Biomedicines</i> , 2022, 10, 204.	3.2	7
173	Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study. <i>American Journal of Hematology</i> , 2022, 97, .	4.3	7
174	Rare manifestations of extramedullary myeloma: testicular plasmacytomas. <i>Leukemia and Lymphoma</i> , 2018, 59, 2002-2004.	1.3	6
175	How I treat rituximab refractory patients with WM. <i>Oncotarget</i> , 2018, 9, 36824-36825.	1.9	6
176	Daratumumab May Attenuate Cardiac Dysfunction Related to Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma: A Prospective Study. <i>Cancers</i> , 2021, 13, 5057.	3.8	6
177	Clinical Outcomes in Patients (Pts) with Dose Reduction of Selinexor in Combination with Bortezomib, and Dexamethasone (XVd) in Previously Treated Multiple Myeloma from the Boston Study. <i>Blood</i> , 2021, 138, 3793-3793.	1.4	6
178	Daratumumab Improves Bone Turnover in Relapsed/Refractory Multiple Myeloma; Phase 2 Study REBUILD. <i>Cancers</i> , 2022, 14, 2768.	3.8	6
179	Circulating Soluble Receptor Activator of Nuclear Factor Kappa B Ligand and C-C Motif Ligand 3 Correlate With Survival in Patients With Waldenström Macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 431-437.	0.4	5
180	Kinetics of anti-SARS-CoV-2 neutralizing antibodies development after BNT162b2 vaccination in patients with amyloidosis and the impact of therapy. <i>American Journal of Hematology</i> , 2022, 97, E27.	4.3	5

#	ARTICLE	IF	CITATIONS
181	Impact of Daratumumab-Containing Induction on Stem Cell Mobilization and Collection, Engraftment and Hospitalization Parameters Among Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation. <i>Blood</i> , 2021, 138, 3886-3886.	1.4	5
182	Efficacy and safety of elotuzumab for the treatment of multiple myeloma. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 1-9.	2.5	4
183	Coexistence of leishmaniasis and multiple myeloma in the era of monoclonal antibody (anti-CD38 or Tj ETQq1 1 0.784314 rgBT /Ove 2018, 59, 983-987.	1.3	4
184	The current role of BTK inhibitors in the treatment of Waldenstromâ€™s Macroglobulinemia. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 663-674.	2.4	4
185	Ibrutinib plus rituximab for the treatment of adult patients with WaldenstrÃ¶mâ€™s macroglobulinemia: a safety evaluation. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 987-995.	2.5	4
186	Bendamustine Plus Rituximab for the Treatment of WaldenstrÃ¶m Macroglobulinaemia: Patient Outcomes and Impact of Bendamustine Dosing. <i>Blood</i> , 2020, 136, 10-11.	1.4	4
187	Growth Differentiation Factor-15 in Patients with Light Chain (AL) Amyloidosis Has Independent Prognostic Significance and Adds Prognostic Information Related to Risk of Early Death and Renal Outcomes. <i>Blood</i> , 2014, 124, 306-306.	1.4	4
188	IMiDs for myeloma induced renal impairment. <i>Oncotarget</i> , 2018, 9, 35476-35477.	1.9	4
189	Nonselective proteasome inhibitors in multiple myeloma and future perspectives. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 335-347.	1.9	4
190	A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2021, 138, 2736-2736.	1.4	4
191	The Addition of IMiDs for Patients with Daratumumab-Refractory Multiple Myeloma Can Overcome Refractoriness to Both Agents. <i>Blood</i> , 2020, 136, 21-21.	1.4	4
192	Diabetes mellitus and multiple myeloma; common features of two distinct entities. <i>Diabetes/Metabolism Research and Reviews</i> , 2022, 38, e3535.	4.0	4
193	Lenalidomide with low- or intermediate-dose dexamethasone in patients with relapsed or refractory myeloma. <i>Leukemia and Lymphoma</i> , 2016, 57, 1776-1780.	1.3	3
194	Renal pathology in patients with monoclonal gammopathy or multiple myeloma: monoclonal immunoglobulins are not always the cause. <i>Leukemia and Lymphoma</i> , 2020, 61, 3247-3250.	1.3	3
195	Continuing Cancer Therapy through the Pandemic While Protecting Our Patients: Results of the Implementation of Preventive Strategies in a Referral Oncology Unit. <i>Cancers</i> , 2021, 13, 763.	3.8	3
196	Integrin expression in correlation to clinicopathological features and prognosis of prostate cancer: A systematic review and meta-analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 221-232.	1.7	3
197	Subdiaphragmatic extranodal localizations at diagnosis of primary mediastinal large B-cell lymphoma: an impressive, rare presentation with no independent effect on prognosis. <i>Leukemia Research</i> , 2021, 107, 106595.	0.9	3
198	Carfilzomib-Associated Renal Toxicity Is Common and Unpredictable: An Analysis of 114 Patients. <i>Blood</i> , 2018, 132, 1966-1966.	1.4	3

#	ARTICLE	IF	CITATIONS
199	Myeloma in the Octogenarians: Disease Characteristics and Clinical Outcomes in the Era of Modern Anti-Myeloma Therapy. <i>Blood</i> , 2014, 124, 4738-4738.	1.4	3
200	Elevated vWF Antigen Serum Levels Are Associated With Poor Prognosis, and Decreased Circulating ADAMTS-13 Antigen Levels Are Associated With Increased IgM Levels and Features of WM but not Increased vWF Levels in Patients With Symptomatic WM. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 23-28.	0.4	2
201	Screening for Gaucher disease among patients with plasma cell dyscrasias. <i>Leukemia and Lymphoma</i> , 2021, 62, 761-763.	1.3	2
202	Pomalidomide Plus Low-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World "POWERFUL" Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 1509.	2.4	2
203	Survival among older patients with previously treated multiple myeloma treated with selinexor, bortezomib, and dexamethasone (XVd) in the BOSTON study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8019-8019.	1.7	2
204	ASSOCIATION OF -308G/A, -238G/A TNF- β POLYMORPHISMS WITH MULTIPLE MYELOMA RISK AND SURVIVAL: A SYSTEMATIC REVIEW AND META-ANALYSIS.. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, , .	0.4	2
205	Utilization and tolerance of beta-blockers among patients with AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2022, 29, 31-37.	3.1	2
206	Elevated Von Willebrand Factor Antigen Serum Levels Are Associated With Poor Prognosis In Patients With Symptomatic Waldenström's Macroglobulinemia. <i>Blood</i> , 2013, 122, 1860-1860.	1.4	2
207	Clinical biomarkers directing the management of patients with colon and lung cancer (beyond) Tj ETQq1 1 0.784314,rgBT /Oyerlock 0.2	0.2	2
208	Metachronous Bilateral Testicular Plasmacytoma After an Initial Soft Tissue, Extramedullary Plasmacytoma. <i>Cureus</i> , 2021, 13, e19517.	0.5	2
209	Newly Diagnosed Multiple Myeloma Patients with Skeletal-Related Events and Abnormal MRI Pattern Have Poor Survival Outcomes: A Prospective Study on 370 Patients. <i>Journal of Clinical Medicine</i> , 2022, 11, 3088.	2.4	2
210	Prognostication of the High-Risk WM Patient. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 127-129.	0.4	1
211	Optimizing therapy in bortezomib-exposed patients with multiple myeloma. <i>Expert Review of Hematology</i> , 2018, 11, 463-469.	2.2	1
212	The Role of TAMIS (Transanal Minimally Invasive Surgery) in the Management of Advanced Rectal Cancer "One Shared Story of Three Exceptional Cases. <i>Journal of Investigative Surgery</i> , 2019, 32, 371-376.	1.3	1
213	Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma Treated with Bortezomib-Based Induction. <i>Journal of Clinical Medicine</i> , 2020, 9, 3201.	2.4	1
214	Response of an oncology unit in the midst of the COVID-19 outbreak. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 1947-1952.	1.0	1
215	A Molecular Signature of Three tRNA-Derived RNA Fragments May Discriminate Smoldering from Symptomatic Multiple Myeloma Patients. <i>Blood</i> , 2019, 134, 5528-5528.	1.4	1
216	The Cumulative Dose But Not The Frequency Of Infusions Is a Risk Factor For The Development Of Osteonecrosis Of The Jaw (ONJ) In Myeloma Patients Who Receive Zoledronic Acid (ZA). <i>Blood</i> , 2013, 122, 3196-3196.	1.4	1

#	ARTICLE	IF	CITATIONS
217	Three Drug Combinations Based on Bortezomib and Dexamethasone (VD) Backbone Improve Renal Function More Efficiently Than VD in Myeloma Patients with Severe Renal Impairment. <i>Blood</i> , 2014, 124, 4769-4769.	1.4	1
218	Ibrutinib for rituximab-refractory Waldenström macro-globulinemia. <i>Oncotarget</i> , 2018, 9, 12536-12537.	1.9	1
219	Clinical Impact of an Early Response and of Early Initiation of Salvage Therapy in Patients with Systemic Light Chain (AL) Amyloidosis. <i>Blood</i> , 2019, 134, 1894-1894.	1.4	1
220	Short Daratumumab Consolidation in Patients with AL Amyloidosis or Lcdd Improves Complete Response Rates and Modifies Bone Marrow Microenvironment. <i>Blood</i> , 2020, 136, 25-25.	1.4	1
221	Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) As a Biomarker of Renal Outcomes in AL Amyloidosis. <i>Blood</i> , 2020, 136, 33-33.	1.4	1
222	T Cell Immunoprofiling of Patients with Relapsed and/or Refractory Myeloma Who Receive Daratumumab Monotherapy: Longitudinal Analysis during 7 Cycle Follow-up of the Rebuild Phase 2 Study. <i>Blood</i> , 2020, 136, 28-28.	1.4	1
223	The role of ibrutinib in Waldenström macroglobulinemia. <i>Expert Opinion on Orphan Drugs</i> , 2018, 6, 85-89.	0.8	0
224	Multiple Myeloma Bone Disease. , 2019, , 329-340.		0
225	Primary plasma cell leukemia presenting as secondary pulmonary alveolar proteinosis. <i>Leukemia and Lymphoma</i> , 2020, 61, 2246-2249.	1.3	0
226	Antibody Therapies for Multiple Myeloma. , 0, , .		0
227	High Bone Turnover Is Present in Patients with Primary Systemic (AL) Amyloidosis and Increased Osteoprotegerin Identifies Patients with Poor Survival within Mayo Stage 1 Disease. <i>Blood</i> , 2014, 124, 2028-2028.	1.4	0
228	Hemodynamic, Functional and Structural Markers of Vascular Involvement in Primary Systemic Light Chain (AL) Amyloidosis. <i>Blood</i> , 2014, 124, 2029-2029.	1.4	0
229	The Combination of Bortezomib and Lenalidomide (VR) Consolidation Post-ASCT, in the Absence of Dexamethasone and Bisphosphonates, Improves Response Rates and Bone Metabolism in Newly Diagnosed Patients with Multiple Myeloma. <i>Blood</i> , 2014, 124, 3462-3462.	1.4	0
230	Amplification of 1q21 Is Associated with Other High Risk Cytogenetic Abnormalities and Has No Independent Prognostic Significance in Patients Treated with Novel Agents. <i>Blood</i> , 2014, 124, 3464-3464.	1.4	0
231	Renal Outcomes in Patients with AL Amyloidosis: Evaluation of Prognostic Factors and Impact of Therapy with Novel Agents. <i>Blood</i> , 2014, 124, 2130-2130.	1.4	0
232	Genetic Factors Related with Early Onset of Osteonecrosis of the Jaw in Patients with Multiple Myeloma Under Zoledronic Acid Therapy. <i>Blood</i> , 2014, 124, 2115-2115.	1.4	0
233	Circulating Adamts-13 Is Reduced in Patients with Waldenström's Macroglobulinemia and Is Associated with Increased IgM Levels and Features of the Disease but Not with the Increased Levels of Von Willebrand Factor. <i>Blood</i> , 2014, 124, 5741-5741.	1.4	0
234	Addition of Cyclophosphamide and Higher Doses of Dexamethasone Do Not Improve Outcomes of Patients with AL Amyloidosis Treated with Bortezomib. <i>Blood</i> , 2016, 128, 4500-4500.	1.4	0

#	ARTICLE	IF	CITATIONS
235	Optimising Treatment in Relapsed, Refractory Multiple Myeloma. <i>European Oncology and Haematology</i> , 2018, 14, 96.	0.0	0
236	Carfilzomib Induces Acute Endothelial Dysfunction Which Correlates with the Occurrence of Cardiovascular Events. <i>Blood</i> , 2018, 132, 3247-3247.	1.4	0
237	Serum Neutrophil Gelatinase-Associated Lipocalin Independently Predicts for Renal Response in Myeloma Patients with Severe Renal Impairment. <i>Blood</i> , 2019, 134, 1877-1877.	1.4	0
238	Pulmonary Function Tests Reveal Unrecognized Lung Dysfunction and Have Independent Prognostic Significance in Patients with Systemic AL Amyloidosis. <i>Blood</i> , 2019, 134, 1842-1842.	1.4	0
239	Kinetics of Anti-Sars-Cov-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers. <i>Blood</i> , 2021, 138, 4202-4202.	1.4	0
240	IMiD Retreatment in Patients Refractory to Both an IMiD and an Anti-CD38 Antibody Induces Significant Response Rates Post Anti-CD38 Exposure. <i>Blood</i> , 2020, 136, 12-12.	1.4	0
241	A Prospective Study and Identification of Genomewide Association Markers of Familial Predisposition to Plasma Cell Dyscrasias. <i>Blood</i> , 2020, 136, 8-8.	1.4	0
242	Efficacy and Tolerability of Daratumumab with Ixazomib and Dexamethasone in Patients with One Prior Lenalidomide-Based Regimen: Preliminary Results of the Phase 2 Daria Study. <i>Blood</i> , 2020, 136, 19-20.	1.4	0
243	Efficacy of Daratumumab Monotherapy on Bone Metabolism of Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results from the Phase 2 Rebuild Study. <i>Blood</i> , 2020, 136, 29-29.	1.4	0
244	Effect of Prior Treatment with Proteasome Inhibitors on the Efficacy and Safety of Once-Weekly Selinexor, Bortezomib, and Dexamethasone in Comparison with Twice-Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Subgroup Analysis from the Boston Study. <i>Blood</i> , 2020, 136, 48-50.	1.4	0
245	The Role of Low Dose Whole Body CT in the Detection of Progression of Patients with Smoldering Multiple Myeloma. <i>Blood</i> , 2020, 136, 6-7.	1.4	0